Menu
Search
|

Menu

Close
X

Ultragenyx Pharmaceutical Inc RARE.OQ (NASDAQ Stock Exchange Global Select Market)

47.12 USD
-0.40 (-0.84%)
As of Feb 16
chart
Previous Close 47.52
Open 47.38
Volume 155,135
3m Avg Volume 209,323
Today’s High 48.16
Today’s Low 46.59
52 Week High 91.17
52 Week Low 41.68
Shares Outstanding (mil) 42.46
Market Capitalization (mil) 2,305.92
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 18 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-3.353
FY16
-6.201
FY15
-3.903
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
19,878.61
5.77
Price to Book (MRQ)
vs sector
5.37
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-62.70
14.43
Return on Equity (TTM)
vs sector
-63.52
16.13

EXECUTIVE LEADERSHIP

Daniel Welch
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Emil Kakkis
President, Chief Executive Officer, Director, Since
Salary: $567,200.00
Bonus: --
Shalini Sharp
Chief Financial Officer, Executive Vice President, Since 2016
Salary: $441,000.00
Bonus: --
Sunil Agarwal
President - Research and Development, Since 2017
Salary: $150,180.00
Bonus: $100,000.00
Karah Parschauer
Executive Vice President, General Counsel, Since 2016
Salary: $175,000.00
Bonus: $50,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

60 Leveroni Ct
NOVATO   CA   94949-5746

Phone: +1415.4838800

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

SPONSORED STORIES